Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors
Status:
Recruiting
Trial end date:
2029-12-31
Target enrollment:
Participant gender:
Summary
The R0 resection rate of gastrointestinal stromal tumor (GIST) with high recurrence risk was
relatively low, and the relapse-free survival rate was relatively low, which needed to be
further improved. A few retrospective analyses and a small sample of prospective studies have
found that neoadjuvant therapy with imatinib mesylate can improve R0 resection rates. Whether
neoadjuvant therapy prolongs long-term survival remains unclear. The primary objective of
this study was to evaluate 5-year progression-free survival (PFS) for GIST patients with high
recurrence risk after neoadjuvant treatment with imatinib mesylate.
Phase:
Phase 2
Details
Lead Sponsor:
First Affiliated Hospital of Zhejiang University
Collaborators:
First Affiliated Hospital of Wenzhou Medical University Ningbo No. 1 Hospital Second Affiliated Hospital, School of Medicine, Zhejiang University Sir Run Run Shaw Hospital Taizhou Hospital of Zhejiang Province Zhejiang Cancer Hospital